Loading clinical trials...
Loading clinical trials...
A study to determine the safety, tolerability, and efficacy of evolocumab (AMG 145) in patients with homozygous familial hypercholesterolemia (HoFH).
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Amgen
NCT07489209 · Homozygous Familial Hypercholesterolemia (HoFH)
NCT07037771 · Homozygous Familial Hypercholesterolemia
NCT01109368 · Homozygous Familial Hypercholesterolemia
NCT06832371 · Homozygous Familial Hypercholesterolemia (HoFH), Major Adverse Cardiovascular Events (MACE), and more
NCT06723652 · Homozygous Familial Hypercholesterolemia
Research Site
New York, New York
Research Site
Cincinnati, Ohio
Research Site
Brussels
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions